StockData

Nephros vs Nexgel

NEPH and NXGL side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How NEPH and NXGL compare

Nexgel is the larger company, worth 1.2 times as much as Nephros ($37.0M against $31.5M).

Nephros grew revenue faster over the last twelve months (24.2% versus 3.4% for Nexgel).

Nephros keeps more of each dollar of sales as profit, with a net margin of 8.4% compared with −51.3% at Nexgel.

Nephros scores higher on the StockData Score (13 against 6 for Nexgel), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricNEPHNXGL
Size and price
Market cap$31.5M$37.0M
Share price$2.90$3.80
Change, 1 year−34.1%−90.1%
Change, 5 years−59.6%–
Beta (5Y)1.751.08
Employees3619
StockData Score
Total score13 (better)6
Valuation score4 (better)2
Growth score2 (better)1
Performance score2 (better)1
Health score5 (better)2
Dividend score00
Valuation
P/E18.1×–
P/S1.5× (better)3.1×
P/B–7.5×
EV/EBITDA15.2×–
Fair value$3.74$12.33
Margin of safety22.5%69.2% (better)
Growth
Revenue growth (TTM)24.2% (better)3.4%
Revenue growth, 5Y average17.0%76.1% (better)
Net income growth (TTM)30.8%–
EPS growth (TTM)33.3%–
Profitability
Gross margin61.3% (better)35.1%
Operating margin7.9% (better)−44.8%
Net margin8.4% (better)−51.3%
Return on equity–−129%
Return on invested capital–−91.0%
Financial health
Debt / equity–0.09
Current ratio4.07 (better)0.43
Altman Z-score−5.18−0.89 (better)
Piotroski F-score7 (better)5
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions48.9%9.0%
Held by insiders9.5%13.2%
Insider net buying, 12 months–$721K
Short interest, % of float0.12%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.